Supply of adagrasib medicine

22 October 2026, 09:00 UTC+02:00 (07:00 UTC)
07:00 AM · UTC
Contract value
PLN 1,040,000

Estimated value excluding VAT; not an award amount.

Contract period
8 months
Published
October 5, 2026

TED (Tenders Electronic Daily)

Overview

Wielkopolskie Centre for Pulmonology and Thoracic Surgery seeks delivery of adagrasib for its Poznań site. The procedure is accelerated because the growing number of oncology patients makes it urgent to preserve continuity of treatment. It is an open, single-lot supply contract with an estimated value of PLN1,040,000 excluding VAT and an eight-month term. The notice does not allow partial tenders because the supply is treated as a single, uniform subject. Price is the sole award criterion. Tenders must be submitted electronically in Polish by 22 October 2026 at 09:00 UTC+02:00. The detailed product specification is in a separate price-form attachment, which was not read. No award is published.',

Information based on the public notice

What the buyer needs

Supply of the medicine adagrasib. The notice cites continuity of oncology treatment as the reason for acceleration.

  • Partial tenders are not allowed; electronic offers in Polish are required. The notice says the detailed product description and price form are in attachment 2, which was not consulted.

Lots

LOT-0004 ·Supply of adagrasib medicine

Tender details

Buyer
Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów
Country
Poland
Procedure
open
Classification
CPV 33652100
Notice reference
686769-2026
Estimated value
PLN 1,040,000 excluding VAT
Term
8 months
Award criterion
Price only
Deadline
22 October 2026, 09:00 UTC+02:00

What to check in the tender documents

  • The public notice does not state the exact dosage, package quantities or award result; detailed product requirements are in the separate attachment, not reviewed.
Get started with Ziva

Original notice

Read the original description

Dostawa leku Adagrasibu

Przedmiotem zamówienia jest dostawa leku Adagrasibu. Zamawiający nie dopuszcza możliwości składania ofert częściowych. Powód braku podziału na części: Przedmiot zamówienia ma jednolity charakter. Szczegółowy opis znajduje się w załączniku nr 2, który jest jednocześnie formularzem cenowym. Procedura przyśpieszona – uzasadnienie: W związku ze wzrostem liczby pacjentów objętych leczeniem onkologicznym zaistniała konieczność pilnego przeprowadzenia postępowania, w celu zapewnienia kontynuacji i ciągłości terapii pacjentom onkologicznym.

Official source: TED (Tenders Electronic Daily) ↗

Official notice PDF ↗